ZA200306124B - Method of treating of demyelinating diseases or conditions. - Google Patents

Method of treating of demyelinating diseases or conditions.

Info

Publication number
ZA200306124B
ZA200306124B ZA200306124A ZA200306124A ZA200306124B ZA 200306124 B ZA200306124 B ZA 200306124B ZA 200306124 A ZA200306124 A ZA 200306124A ZA 200306124 A ZA200306124 A ZA 200306124A ZA 200306124 B ZA200306124 B ZA 200306124B
Authority
ZA
South Africa
Prior art keywords
treating
conditions
demyelinating diseases
demyelinating
diseases
Prior art date
Application number
ZA200306124A
Other languages
English (en)
Inventor
Craig P Smith
Margaret Petty
Michel P Rathbone
David Rampe
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ZA200306124B publication Critical patent/ZA200306124B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
ZA200306124A 2001-02-15 2003-08-07 Method of treating of demyelinating diseases or conditions. ZA200306124B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15

Publications (1)

Publication Number Publication Date
ZA200306124B true ZA200306124B (en) 2004-11-08

Family

ID=23024747

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200306124A ZA200306124B (en) 2001-02-15 2003-08-07 Method of treating of demyelinating diseases or conditions.

Country Status (39)

Country Link
US (10) US6967210B2 (ru)
EP (1) EP1368031A2 (ru)
JP (3) JP2004518711A (ru)
KR (3) KR100951542B1 (ru)
CN (2) CN1529598A (ru)
AP (1) AP1749A (ru)
AR (1) AR035750A1 (ru)
AU (3) AU2002247200B9 (ru)
BR (1) BR0207272A (ru)
CA (1) CA2438712A1 (ru)
CO (1) CO5390085A1 (ru)
CR (1) CR7023A (ru)
CZ (1) CZ20032172A3 (ru)
EA (2) EA011319B1 (ru)
EC (1) ECSP024218A (ru)
EE (1) EE200300363A (ru)
GB (1) GB0119435D0 (ru)
HK (1) HK1080361B (ru)
HR (1) HRP20030652A2 (ru)
HU (1) HUP0303203A3 (ru)
IL (2) IL157341A0 (ru)
MA (1) MA26152A1 (ru)
ME (1) MEP21208A (ru)
MX (1) MXPA03006110A (ru)
MY (1) MY157745A (ru)
NO (1) NO20033622L (ru)
NZ (4) NZ527011A (ru)
OA (1) OA12549A (ru)
PA (1) PA8540101A1 (ru)
PE (1) PE20040175A1 (ru)
PL (1) PL363638A1 (ru)
SG (1) SG134170A1 (ru)
SK (1) SK10392003A3 (ru)
TR (4) TR200800691T2 (ru)
TW (1) TWI325319B (ru)
UA (2) UA80394C2 (ru)
WO (1) WO2002064126A2 (ru)
YU (1) YU62903A (ru)
ZA (1) ZA200306124B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
AU2003301184A1 (en) * 2002-12-20 2004-07-22 Dynogen Pharmaceuticals Inc METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS
JP2006515327A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド ナトリウムチャネル調節因子を用いた下部尿路障害を処置するための方法
EP1721607A1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
CN102822979B (zh) * 2010-03-26 2015-08-26 株式会社半导体能源研究所 半导体器件
WO2012009204A1 (en) * 2010-07-15 2012-01-19 The Trustees Of Columbia University In The City Of New York Methods for diagnosing and treating concussive disorders
US20130030025A1 (en) * 2011-01-28 2013-01-31 Wessel Thomas C Use of potassium channel blockers to treat cerebral palsy
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2019126643A1 (en) * 2017-12-22 2019-06-27 Massachusetts Institute Of Technology Compositions and methods for williams syndrome (ws) therapy
WO2022159086A1 (en) * 2021-01-20 2022-07-28 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
ATE115143T1 (de) * 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
DK0415103T3 (da) * 1989-08-02 1995-06-19 Hoechst Roussel Pharma 2,3-Dihydro-1-(pyridinylamino)-indoler, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
DE69912250T2 (de) * 1998-01-29 2004-07-29 Bristol-Myers Squibb Co., Wallingford Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon
AU5483500A (en) * 1999-07-09 2001-01-30 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
TR200301330T2 (tr) 2004-12-21
CZ20032172A3 (cs) 2004-01-14
CR7023A (es) 2003-11-17
AP2003002834A0 (en) 2003-09-30
US20040157889A1 (en) 2004-08-12
US20090209595A1 (en) 2009-08-20
HUP0303203A3 (en) 2007-11-28
HRP20030652A2 (en) 2005-06-30
US20040157888A1 (en) 2004-08-12
EA200300882A1 (ru) 2003-12-25
MXPA03006110A (es) 2005-07-01
HK1080361A1 (en) 2006-04-28
WO2002064126A2 (en) 2002-08-22
WO2002064126A3 (en) 2003-02-20
ECSP024218A (es) 2003-09-24
TR200800693T2 (tr) 2008-07-21
KR20090005254A (ko) 2009-01-12
UA80394C2 (en) 2007-09-25
SG134170A1 (en) 2007-08-29
EA200600896A1 (ru) 2006-08-25
HK1080361B (zh) 2009-10-30
OA12549A (en) 2006-06-05
US20050159456A1 (en) 2005-07-21
US20090270458A1 (en) 2009-10-29
TR200800691T2 (tr) 2008-03-21
CN1529598A (zh) 2004-09-15
US7179821B2 (en) 2007-02-20
US20030105150A1 (en) 2003-06-05
KR100951542B1 (ko) 2010-04-09
NO20033622D0 (no) 2003-08-14
CN1679564A (zh) 2005-10-12
JP2004518711A (ja) 2004-06-24
EE200300363A (et) 2003-10-15
MEP21208A (en) 2010-06-10
AP1749A (en) 2007-06-13
AU2008201179B2 (en) 2009-08-20
AR035750A1 (es) 2004-07-07
GB0119435D0 (en) 2001-10-03
IL157341A (en) 2010-11-30
MA26152A1 (fr) 2004-07-01
PE20040175A1 (es) 2004-03-29
NZ539159A (en) 2006-11-30
BR0207272A (pt) 2004-02-10
CA2438712A1 (en) 2002-08-22
US7534803B2 (en) 2009-05-19
US6967210B2 (en) 2005-11-22
UA88773C2 (ru) 2009-11-25
KR20040014459A (ko) 2004-02-14
EA012409B1 (ru) 2009-10-30
KR100951540B1 (ko) 2010-04-09
PA8540101A1 (es) 2003-09-05
US20060025452A1 (en) 2006-02-02
NZ527011A (en) 2005-07-29
HUP0303203A2 (hu) 2003-12-29
AU2009238332A1 (en) 2009-12-10
MY157745A (en) 2016-07-15
TR200800692T2 (tr) 2008-03-21
NZ556697A (en) 2009-01-31
YU62903A (sh) 2006-05-25
PL363638A1 (en) 2004-11-29
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01
EA011319B1 (ru) 2009-02-27
NO20033622L (no) 2003-10-06
CN100522164C (zh) 2009-08-05
US20090209594A1 (en) 2009-08-20
IL157341A0 (en) 2004-02-19
JP2009185045A (ja) 2009-08-20
CO5390085A1 (es) 2004-04-30
US7230015B2 (en) 2007-06-12
KR20090005255A (ko) 2009-01-12
AU2002247200B2 (en) 2007-12-13
US20050234105A1 (en) 2005-10-20
EP1368031A2 (en) 2003-12-10
US20090281147A1 (en) 2009-11-12
JP2010120958A (ja) 2010-06-03
AU2002247200B9 (en) 2008-07-10
NZ544720A (en) 2007-08-31
AU2008201179A1 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
GB2393202B (en) Methods of well treatment
ZA200108446B (en) Novel method of treatment.
ZA200306124B (en) Method of treating of demyelinating diseases or conditions.
GB0129976D0 (en) Treatment method
EP1404339A4 (en) METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS VI
HK1064261A1 (en) Method for the treatment of tobacco.
EP1450820A4 (en) METHOD OF TREATING AND PREVENTING INFLAMMATORY DISEASES
GB2389532B (en) The method of treating cancer
AU2002229986A1 (en) Method of treating neurological diseases
EP1389105A4 (en) METHOD OF TREATMENT
GB0120147D0 (en) Treatment method
GB0112216D0 (en) Method of treatment
GB0118892D0 (en) Method of treatment
AUPR381601A0 (en) Method of treating respiratory conditions
AUPR731901A0 (en) Method of treatment
IL161630A0 (en) Methods of treating endometreosis
GB0126253D0 (en) Treatment method
GB0105703D0 (en) Method of animal treatment
GB0126094D0 (en) Method of treatment
GB0111487D0 (en) Method of treatment
GB0125105D0 (en) Method of treatment
GB0116029D0 (en) Method of treatment
AU2002257731A1 (en) Method of well treatment
GB0102927D0 (en) Treatment method